Zhenzhou
Zhenzhou
Zhenzhou, Henan, China15 results · Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| A Study to Learn the Safety and Efficacy of HLX37 in Combination With Chemotherapy for First-line Treatment in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer | Neoplasms by Site, Thoracic Neoplasms, bronchial neoplasm, bronchogenic carcinoma, lung disorder, lung neoplasm, neoplasm, non-small cell lung carcinoma, respiratory system disorder, respiratory tract neoplasm | Not yet recruiting | Phase 2 / Phase 3 | 2026-10-08 | NCT07865910 | |
| A Study of TAK-360 in People With Narcolepsy or Idiopathic Hypersomnia | Disorders of Excessive Somnolence, Dyssomnias, Sleep Disorders, Intrinsic, idiopathic hypersomnia, narcolepsy without cataplexy, narcolepsy-cataplexy syndrome, nervous system disorder, psychiatric disorder, sleep-wake disorder | Recruiting | Phase 2 / Phase 3 | 2026-09-18 | NCT07646678 | |
| SG301-SC Injection Safety Study in Subjects With Primary ITP Patients | Cytopenia, Hemic and Lymphatic Diseases, Hemorrhage, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Purpura, Thrombocytopenic, Idiopathic, Signs and Symptoms, Skin Manifestations, autoimmune disease, blood coagulation disease, blood platelet disease, hematologic disorder, hemorrhagic disease, immune system disorder, purpura, thrombocytopenia, thrombocytopenic purpura, thrombotic microangiopathy | Recruiting | Phase 2 | 2026-09-09 | NCT07710248 | |
| Efficacy and Safety of Roflumilast Foam 0.3% in Trial Participants With Seborrheic Dermatitis | Skin Diseases, Eczematous, Skin Diseases, Papulosquamous, Skin and Connective Tissue Diseases, dermatitis, sebaceous gland disorder, seborrheic dermatitis, skin disorder | Not yet recruiting | Phase 3 | 2026-08-21 | NCT07683806 | |
| A Study of A166 in Patients With HER2-Positive Unresectable or Metastatic Breast Cancer | Her 2 Positive Breast Cancer | Recruiting | Phase 2 | 2026-05-08 | NCT07299825 | |
| Efficacy of S.T.O.P®KIT in Retarding Axial Length Growth in Children With Low Hyperopia | eye disorder, hyperopia, refractive error | Not yet recruiting | Not applicable | 2026-02-10 | NCT07401511 | |
| A Prospective Cohort Study of Zorifertinib as a First-line Treatment in Patients With Epidermal Growth Factor Receptor-mutant Advanced Non-small Cell Lung Cancer With Central Nervous System (CNS) Metastases | Neoplasm Metastasis, Neoplastic Processes, Pathologic Processes, Pathological Conditions, Signs and Symptoms, neoplasm | Recruiting | Not stated | 2026-02-09 | NCT07143045 | |
| Safety and Efficacy of Tocilizumab in Patients With Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease | autoimmune disease, autoimmune disorder of the nervous system, immune system disorder, myelin oligodendrocyte glycoprotein antibody-associated disease | Active, not recruiting | Phase 2 / Phase 3 | 2026-01-08 | NCT06452537 | |
| Evaluation of Rovadicitinib Compared to the Protocol Selected by Researchers in Third Line and Subsequent Studies of Moderate to Severe Chronic Graft-versus-host Disease | graft versus host disease, immune system disorder | Recruiting | Phase 3 | 2025-12-08 | NCT06682169 | |
| ICP-248 in Combination With Orelabrutinib in Treatment-naïve Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (APEX-03) | Hemic and Lymphatic Diseases, Neoplasms by Site, hematologic disorder, hematopoietic and lymphoid system neoplasm, neoplasm | Recruiting | Phase 2 / Phase 3 | 2025-11-21 | NCT06378138 | |
| Study of APG2575 Single Agent and Combination Therapy in Patients With Relapsed/Refractory CLL/SLL | B-cell chronic lymphocytic leukemia, Chronic Disease, Disease Attributes, Hemic and Lymphatic Diseases, Leukemia, B-Cell, Neoplasms by Histologic Type, Pathologic Processes, Pathological Conditions, Signs and Symptoms, hematologic disorder, immune system disorder, immunoproliferative disorder, leukemia, lymphatic system disorder, lymphoid leukemia, lymphoproliferative syndrome, neoplasm | Recruiting | Phase 1 / Phase 2 | 2025-04-16 | NCT04494503 | |
| FlashPoint Renal Denervation Under Columbus 3D Mapping System Guidance for Treating Hypertension | cardiovascular disorder, hypertensive disorder, vascular disorder | Recruiting | Not applicable | 2024-11-20 | NCT05590871 | |
| JY231(JY231) Injection for the Treatment of Relapsed or Refractory B Cell Lymphoma/ Leukemia | B-ALL; B-NHL | Recruiting | Not applicable | 2024-11-07 | NCT06678282 | |
| Blinatumomab for Relapsed Acute B Lymphoblastic Leukemia After Transplantation | Disease Attributes, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Recurrence | Recruiting | Phase 4 | 2024-04-01 | NCT06339775 | |
| YK-029A as First-Line Treatment Versus Platinum-Based Chemotherapy for Non-Small Cell Lung Cancer (NSCLC) With EGFR Exon 20 Insertion Mutations | Neoplasms by Site, Thoracic Neoplasms, bronchial neoplasm, bronchogenic carcinoma, lung disorder, lung neoplasm, neoplasm, non-small cell lung carcinoma, respiratory system disorder, respiratory tract neoplasm | Not yet recruiting | Phase 3 | 2023-04-05 | NCT05767892 |